Scientists have identified a new genetic cause of autism and intellectual disability — and traced it to an unexpected place: the molecular pumps that keep brain cells from drowning in their own calcium. In a study published on 1 July 2026 in the journal Genome Medicine, an international consortium describes de novo mutations in NPTN, the gene encoding the synaptic protein neuroplastin, in eight children with mild-to-severe developmental delay, several of them also diagnosed with autism spectrum disorder. The work promotes a gene long suspected of shaping the human mind into the definitive catalogue of neurodevelopmental disease genes, and it exposes a strikingly mechanical mechanism of illness. When neuroplastin falters, the plasma membrane calcium ATPases it anchors lose their footing, calcium floods the neuronal cytoplasm, and the electrochemical dialogue at the synapse — the basis of learning, memory and social behavior — breaks down.
For the families involved, the results end diagnostic journeys that often stretch on for years without an answer. Developmental delay, frequently accompanied by intellectual disability and autism, affects roughly one to three percent of children worldwide, and its cause remains unknown in about 60 percent of affected cases. Modern sequencing has been steadily shrinking that gap: exome and genome studies show that 40 to 60 percent of individuals with undiagnosed developmental delay, and 30 to 39 percent of autism cases, carry pathogenic de novo variants — mutations that appear in the child but in neither parent. The research team used trio exome sequencing, in which the affected child and both parents are sequenced together, to screen eight individuals recruited through the online matchmaking platform GeneMatcher, with clinicians from multiple countries contributing cases. Each child carried a de novo variant in NPTN and no convincing pathogenic change in any known rare-disease gene. The variants were absent from the gnomAD population database, mapped to the canonical NPTN transcript, and classified under American College of Medical Genetics criteria; the investigation was conducted with informed consent and approval from the ethics committee of the University of Leipzig.
Neuroplastin is hardly a household name, but its résumé is remarkable. The NPTN gene produces two principal isoforms in the human brain: neuroplastin-55, expressed broadly in neural tissue, and neuroplastin-65, which is specific to neurons. Both are type I transmembrane glycoproteins of the immunoglobulin superfamily — rod-like proteins studded with antibody-like domains — and both concentrate at synapses, the contact points where neurons exchange chemical signals. The gene is active early and stays active long: neuroplastin messenger RNA appears at high levels across fetal brain regions between 19 and 24 post-coital weeks and reaches peak abundance in the prefrontal cortex of eighteen-year-old individuals, a region central to planning, self-control and social cognition. Because the two isoforms differ in parts of their sequence, some mutations strike both proteins at once, while others damage only the neuronal version. Their most consequential job, however, has only recently come into focus. Neuroplastin-55 and -65 are obligatory binding partners within the protein complexes of more than 95 percent of the four plasma membrane calcium ATPases, PMCA1 through PMCA4 — meaning that without neuroplastin, these pumps cannot assemble and function properly at the cell surface.
That dependency matters because PMCAs are the neuron’s calcium gatekeepers. They are ATP-fed calcium–proton co-transporters that pump calcium ions with extraordinary speed out of the cell and toward the extracellular space, reinstating resting cytosolic levels after every burst of neural activity and thereby regulating intracellular calcium signaling. Beyond mopping up calcium, PMCA pumps help establish the alkaline microenvironment around the synapse that ionotropic glutamate receptors of the NMDA type require for activation — and NMDA receptors are the molecular switches at the heart of synaptic plasticity, learning and memory. Mutations in the genes encoding PMCA1 through 4, known as ATP2B1 through ATP2B4, have already been linked to developmental delay, autism and other neurodevelopmental disorders, each time with the same cellular signature: diminished pump expression or activity and defective restoration of cytosolic calcium. The connection runs deeper still. The expression, stabilization and activity of the pumps depend strongly on neuroplastin binding, and mice lacking Nptn lose massive amounts of PMCA protein and suffer cognitive impairments along with deficits in social and affective behaviors.
The eight NPTN variants described in the study fall into two mechanistic classes. Four affect both isoforms, disrupting the shared backbone of the protein; four affect only neuroplastin-65, through changes in portions of the protein that the neuronal isoform alone contains. Most striking are two unrelated individuals who independently carry the identical nonsense variant — a premature stop signal that truncates the protein — predicted to cause haploinsufficient production of all neuroplastin isoforms, leaving every relevant cell with effectively half its normal supply. Other children carried frameshift mutations, which scramble the protein’s reading frame, and missense substitutions, which swap single amino acids. The genetic backdrop is equally suggestive. NPTN is frequently deleted or duplicated in patients with 15q24 microdeletion syndrome, a chromosomal disorder associated with developmental delay, and a single-nucleotide polymorphism in the NPTN promoter has been associated with thinner frontal and temporal lobes in the left hemisphere of the brain, correlating with intellectual, verbal and non-verbal abilities in adolescents. Earlier work in mice lacking both copies of Nptn had already demonstrated that normal neuroplastin levels are necessary for multiple cognitive functions.
To test whether reduced gene dosage alone could reproduce the human condition, the researchers studied heterozygous Nptn+/− mice, animals carrying a single functional copy of the gene. These mice produced reduced amounts of both neuroplastin and PMCA, confirming in living brain tissue the biochemical coupling that the human genetics implied. Behavior followed. In the three-chamber social test, the standard assay of rodent sociability, each mouse explored three connected compartments in ten-minute phases: first alone for habituation, then alongside one unfamiliar mouse held in a wire cup, and finally with a second newcomer added to the opposite cup. Typical mice gravitate toward novelty, spending more time with the new arrival. The Nptn+/− mice lost that preference, treating stranger and acquaintance with comparable indifference — an endophenotype analog of the social deficits that characterize autism spectrum disorder, detected through repeated-measures analysis of variance with matched littermate controls.
For the missense variants, the team interrogated protein structure before ever touching a cell. Multiple computational predictors — CADD, REVEL, MutPred2, VEST4 and BayesDel — flagged the substitutions as deleterious. Molecular dynamics simulations, run with the Gromacs package and the OPLS-AA force field in explicit water over 100-nanosecond trajectories at physiological temperature and pressure, revealed structural and thermodynamic abnormalities in the mutant proteins. One variant, P342L, was modeled with the Rosetta suite and docked against human PMCA1 and PMCA2 to examine whether the amino acid change, located within the intermembrane space, might weaken the pump-binding interface; another, W135R, was analyzed at the neuroplastin dimer interface, where the protein pairs with itself. When the mutant genes were expressed in human embryonic kidney cells and measured by quantitative Western blotting, the variant proteins accumulated at lower levels than their wild-type counterpart — evidence that the substitutions destabilize neuroplastin itself, not merely its interactions.
The decisive experiment came in living neurons. The researchers cultured hippocampal neurons from embryonic rats, introduced wild-type or mutant human neuroplastin at days ten to eleven in vitro, and co-expressed genetically encoded calcium indicators — GCaMP5G and jGCaMP7f — fluorescent proteins that brighten instantly whenever cytosolic calcium rises. At days fourteen to sixteen, the neurons were stimulated with brief biphasic electrical pulses delivered through field electrodes, and the resulting calcium transients were captured on high-sensitivity cameras and quantified in Fiji/ImageJ. In neurons expressing wild-type neuroplastin, calcium surged and cleared as expected, pumped back down by working PMCA complexes. In neurons expressing the mutant variants, that regulation failed: statistical comparisons using Mann-Whitney U and Wilcoxon matched-pairs tests confirmed that evoked cytosolic calcium transients were no longer properly controlled. The variants, in other words, did not merely weaken the protein — they dismantled the calcium-control machinery that depends on it.
A final test in fruit flies drove the point home with evolutionary force. The researchers generated transgenic Drosophila carrying human neuroplastin-55 under experimental control, integrated into a defined chromosomal landing site on the second chromosome by PhiC31-mediated transformation. Eliminating the fly’s own neuroplastin ortholog is lethal; supplying the human gene in its wild-type form can stand in for the missing protein, a testament to how deeply conserved this molecule’s function is across hundreds of millions of years of divergent evolution. Yet a missense mutation compromising the PMCA interaction failed to prevent that lethal phenotype. Neuroplastin’s indispensability, the result implies, does not reside in some insect-specific role but in the universal business of calcium management at the cell membrane.
Taken together, the evidence sketches a new disease with unusual internal coherence: a neurodevelopmental disorder marked by intellectual disability and autism that originates either from haploinsufficient NPTN gene dosage or from insufficient functionality of mutant neuroplastin — both routes converging on PMCA hypofunction and calcium dysregulation in central neurons. For clinicians, the study adds NPTN to the short list of genes that merit close scrutiny when exome sequencing returns unexplained results in children with developmental delay, and it delivers the immediate, practical currency of diagnosis: a name, a mechanism and a growing community of families connected through matchmaking platforms. For neuroscientists, it cements calcium handling as one of the convergent pathways in autism biology and elevates neuroplastin from a synaptic curiosity to a lynchpin of neuronal physiology whose loss undermines the pumps, the pH balance and the receptors on which cognition depends. The study, published open access in Genome Medicine as volume 18, article 93, points to next steps that include screening larger undiagnosed cohorts for additional NPTN variants and testing whether boosting calcium pump function can rescue struggling neurons — laboratory questions today, but potentially tomorrow’s therapeutic foothold for children whose brains have been quietly losing their grip on calcium control all along.
Subject of Research: De novo variants in the NPTN gene causing a neurodevelopmental disorder with autism and intellectual disability through neuroplastin–PMCA calcium pump hypofunction
Subject of Research: Medicine
Article Title: A Broken Calcium Switch: New Genetic Disorder Links NPTN Mutations to Autism and Intellectual Disability
Article References: Liang, Y., Ormazabal-Toledo, R., Srinivasan, H., Malci, A., Acevedo, W., Thomas, U., Cohen, J. S., Rahner, N., Luppe, J., Vera, G., Lecoquierre, F., Kroin, E., Angle, B., Cui, H., Sacoto, M. J. G., de Vries, B. B. A., Pfundt, R., Prinzing, G., Wiltrout, K., … Herrera-Molina, R. (2026). De novo variants in NPTN cause a neurodevelopmental disorder with autism and neuroplastin-PMCA hypofunction. Genome Medicine, 18(1), Article 93. https://doi.org/10.1186/s13073-026-01699-7
Image Credits: AI Generated
DOI: 10.1186/s13073-026-01699-7
Keywords: NPTN; neuroplastin; de novo variants; autism spectrum disorder; intellectual disability; developmental delay; PMCA; calcium signaling; haploinsufficiency; neurodevelopmental disorder
Cite Scienmag News
APA MLA Chicago
Juliet Wilcox. (August 30, 2026). NPTN gene variants linked to autism through disrupted brain cell signaling. Scienmag. https://scienmag.com/nptn-gene-variants-linked-to-autism-through-disrupted-brain-cell-signaling/
Juliet Wilcox. “NPTN gene variants linked to autism through disrupted brain cell signaling.” Scienmag, 30 August 2026, https://scienmag.com/nptn-gene-variants-linked-to-autism-through-disrupted-brain-cell-signaling/. Accessed 30 August 2026.
Juliet Wilcox. “NPTN gene variants linked to autism through disrupted brain cell signaling.” Scienmag. August 30, 2026. https://scienmag.com/nptn-gene-variants-linked-to-autism-through-disrupted-brain-cell-signaling/
Copy citation Download RIS
Tags: advances in genome sequencing for autism diagnosiscalcium regulation and neuronal communicationcalcium regulation in neuronscalcium signaling disruption in neuronsde novo mutations in neurodevelopmental genesde novo mutations in neuroplastin genegenetic basis of learning and memory deficitsgenetic causes of neurodevelopmental disordersgenetic diagnosis of autism and intellectual disabilitygenetic mutations causing intellectual disabilityimpact of calcium dysregulation on neuronal communicationimpact of gene mutations on learning and memorymolecular mechanisms of autism spectrum disorderneurodevelopmental disease gene identificationneuroplastin protein role in brain developmentNPTN gene variants and autismplasma membrane calcium ATPases and neuronal healthplasma membrane calcium ATPases functionsynaptic protein dysfunction in autismsynaptic signaling disruption in neurodevelopmental disorders
